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Dr Hellstrom proposes a hemostasis-related spasm rather than ␣-adrenergic coronary vasoconstriction to explain the decreased myocardial perfusion and function that we observed after coronary stenting and that we resolved by either phentolamine or urapidil. We discussed the involvement of hemostasis-related factors (page 488, right column, 2nd paragraph) 1 but found it played a minor role. In particular, in the experimental study by Heusch et al, 2 ischemia increased the activity of the cardiac sympathetic nerves. Aspirin pretreatment did not influence the traffic along the cardiac sympathetic nerves. Only the segmental anesthesia of cardiac innervation prevented the nerve firing. In addition, our patients were treated with full doses of aspirin and ticlopidine, with such treatment beginning 24 hours after thrombolysis. Also in our patients, heparin (100 U/kg) was injected during coronary stenting.
Activated platelets release vasoactive substances, but the combined antiplatelet and anticoagulant treatment attenuates both intrinsic and extrinsic coagulation pathways. 3, 4 Hemostasis activation did not increase during the procedure, irrespective of the magnitude of endothelial or plaque abrasion (rotational ablation or coronary stenting). Moreover, vasoconstriction did not correlate with thrombin generation. 3 Patients were never in a condition of no-reflow but in a condition of left ventricular function changes that correlated with macrocirculatory and microcirculatory perfusion changes. 5 The impairment of left ventricular function that was observed both in the infarct-related artery-and the non-infarct-related artery-dependent myocardium does not exclude the influence of locally released factors but strongly suggests the involvement of cardio-cardiac and cardiosympathetic reflexes 2 and the electrical syncytium demonstrated among the cardiac cells. 6 H. Richard Hellstrom -Adrenergic Blockade in Myocardial Infarction α
